Dr. An Duy Tran joined the Health Economics Unit in the Centre for Health Policy in October 2016 as a Senior Research Fellow on a full-time appointment. He was previously a Post-doctoral Researcher in Medical Technology Assessment at the CAPHRI School for Public Health and Primary Care of Maastricht University, and Assistant Professor at the Julius Center for Health Sciences and Primary Care of the University Medical Center Utrecht in The Netherlands.
Dr. Tran's research interests include development of simulation models to predict health outcomes in patients with chronic diseases, and perform economic evaluation of interventions using decision analytic modelling. He has substantial experience in designing health economic sub-studies for clinical trials, and performing trial-based cost-effectiveness and cost-utility analyses. He is a Senior Adviser of the Melbourne Clinical and Translational Sciences Research Platform where he provides support for development of clinical trial protocols and grant proposals. He is also a member of the Human Research Ethics Committee of the Melbourne School of Population and Global Health. An Duy Tran is the developer of the first Android and iOS mobile apps for cardiovascular risk assessment in Indigenous Australians (Indigenous CVD Risk Calculator), which are based on the first prediction models of their kind that he and his colleagues developed in 2019.
Find out more about An Duy Tran's experience
An Duy Tran's highlights
An Duy Tran's selected work
An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treat..
Displaying the 10 most recent projects by An Duy Tran.
Displaying the 38 most recent scholarly works by An Duy Tran.
A Patient-Level Model to Estimate Lifetime Health Outcomes of Patients With Type 1 Diabetes
An Tran-Duy, Josh Knight, Andrew J Palmer, Dennis Petrie, Tom WC Lung, William H Herman, Bjorn Eliasson, Ann-Marie Svensson, Philip M Clarke
Journal article | 2020 | Diabetes Care
OBJECTIVE: To develop a patient-level simulation model for predicting lifetime health outcomes of patients with type 1 diabetes an..
Development and Use of Prediction Models for Classification of Cardiovascular Risk of Remote Indigenous Australians
A Tran-Duy, Robyn McDermott, Josh Knight, Xinyang Hua, Elizabeth LM Barr, Kerry Arabena, Andrew Palmer, Philip Clarke
Journal article | 2020 | Heart, Lung and Circulation
Background: Cardiovascular disease (CVD) is the leading cause of death for Indigenous Australians. There is widespread belief that..
The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood
Seamus Kent, Frauke Becker, Talitha Feenstra, Tran-Duy An, Iryna Schlackow, Michelle Tew, Ping Zhang, Wen Ye, Lizheng Shi, William Herman, Phil McEwan, Wendelin Schramm, Alastair Gray, Jose Leal, Mark Lamotte, Michael Willis, Andrew J Palmer, Philip Clarke
Journal article | 2019 | PHARMACOECONOMICS
Transparency in health economic decision modelling is important for engendering confidence in the models and in the reliability of..
Multicentre randomised double-blind placebo controlled trial of combination vancomycin and cefazolin surgical antibiotic prophylaxis: the Australian surgical antibiotic prophylaxis (ASAP) trial
Trisha Peel, Sarah Astbury, Allen C Cheng, David Paterson, Kirsty Buising, Tim Spelman, Tran-Duy An, Richard S de Steiger, Peter Choong, Allen Cheng, David Paterson, Kirsty Buising, Michelle Dowsey, Ross Crawford, Tim Spelman, Philip Clarke, Ben Howden, Peter Rehfisch, Robert Molnar, Sam Adie, et al.
Journal article | 2019 | BMJ Open
INTRODUCTION: Resistant Gram-positive organisms, such as methicillin-resistant staphylococci, account for a significant proportion..
Chewing gum to treat postoperative nausea and emesis in female patients (CHEWY): rationale and design for a multicentre randomised trial
Jai Darvall, Britta Sylvia von Ungern-Sternberg, Sabine Braat, David Story, Andrew Davidson, Megan Allen, Tran-Duy An, Dana Middleton, Kate Leslie
Journal article | 2019 | BMJ OPEN
IMPACT OF COMORBID CONDITIONS ON HEALTH CARE EXPENDITURE AND WORK-RELATED OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RETROSPECTIVE ANALYSIS USING THE MEDICAL EXPENDITURE PANEL SURVEY IN THE PERIOD 2006-2015
MV Vu, N Carvalho, R Buchbinder, G McColl, PM Clarke, A Tran-Duy
Conference Proceedings | 2019 | Value in Health
Use of proton pump inhibitor and risk of iron deficiency: a population‐based case‐control study
A Tran-Duy, Niels Connell, Floris Vanmolkot, Patrick Souverein, Niek de Wit, Coen Stehouwer, Arno Hoes, Frank de Vries, Anthonius de Boer
Journal article | 2019 | Journal of Internal Medicine
BACKGROUND: Hypochlorhydric states are an important cause of iron deficiency (ID). Nevertheless, the association between therapy w..
An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity Results From a Pragmatic Open-Label Trial
An Tran-Duy, Marjan Ghiti Moghadam, Martijn AH Oude Voshaar, Harald E Vonkeman, Annelies Boonen, Philip Clarke, Geoff McColl, Peter M ten Klooster, TR Zijlstra, Willem F Lems, N Riyazi, EN Griep, JMW Hazes, Robert Landewe, Hein J Bernelot Moens, Piet LCM van Riel, Mart AFJ van de Laar, TL Jansen
Journal article | 2018 | Arthritis and Rheumatology
Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge
Andrew J Palmer, Lei Si, Michelle Tew, Xinyang Hua, Michael S Willis, Christian Asseburg, Phil McEwan, Jose Leal, Alastair Gray, Volker Foos, Mark Lamotte, Talitha Feenstra, Patrick J O'Connor, Michael Brandle, Harry J Smolen, James C Gahn, William J Valentine, Richard F Pollock, Penny Breeze, Alan Brennan, et al.
Journal article | 2018 | VALUE IN HEALTH
Increased Eligibility for Attempting Treatment-Free Remission (TFR) with Frontline Nilotinib (NIL) vs Imatinib (IM) in Patients with Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia (CML): Results of a Stochastic Simulation Model
Francois-Xavier Mahon, An Tran-Duy, Raechelle G Ocampo, David Ray, Estella Mendelson, Aby Buchbinder, Pascal Edrich, Sonya J Snedecor, Giuseppe Saglio
Conference Proceedings | 2015 | BLOOD
Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-alpha antagonists in management of ankylosing spondylitis: a dynamic population modelling study
An Tran-Duy, Annelies Boonen, Mart AFJ van de Laar, Johan L Severens
Journal article | 2015 | COST EFFECTIVENESS AND RESOURCE ALLOCATION
Early cost-utility analysis of general and cerebrospinal fluid-specific Alzheimer's disease biomarkers for hypothetical disease-modifying treatment decision in mild cognitive impairment
Ron LH Handels, Manuela A Joore, An Tran-Duy, Anders Wimo, Claire AG Wolfs, Frans RJ Verhey, Johan L Severens
Journal article | 2015 | Alzheimer's & Dementia
Should patients prescribed long-term low-dose aspirin receive proton pump inhibitors? Systematic review and meta-analysis
An duy Tran, Floris Vanmolkot, Manuela Joore, Hoes Hoes, Coen Stehouwer
Conference Proceedings | 2014 | Medical Decision Making
Purpose: Several clinical guidelines recommend the use of proton pump inhibitors (PPIs) in patients taking low-dose aspirin. Altho..
Comparison Of The Cost-Effectiveness Of The Treatment Strategies With and Without Biological Response Modifiers For Patients With Recently Diagnosed Rheumatoid Arthritis Following A Clinical Guideline For Treatment Selection
An Tran-Duy, Annelies Boonen, Wietske Kievit, Piet LCM van Riel, Mart AFJ van de laar, Johan L Severens
Conference Proceedings | 2013 | ARTHRITIS AND RHEUMATISM
SIMULTANEOUSLY MODELLING HEALTH IMPACT, BUDGET IMPACT AND COST-EFFECTIVENESS IN THE CONTEXT OF POPULATION DYNAMICS: THE CASE OF TUMOUR NECROSIS FACTOR-ALPHA ANTAGONIST FOR ANKYLOSING SPONDYLITIS IN THE DUTCH SOCIETY
A Tran-Duy, A Boonen, MAFJ van de Laar, JL Severens
Conference Proceedings | 2012 | CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
Consequences of withdrawing the second tumour necrosis factor alpha antagonist in sequential treatments of active ankylosing spondylitis: a health-economical perspective using a population dynamics simulation model
An duy Tran, Annelies Boonen, Johan Severens
Conference Proceedings | 2011 | Medical Decision Making
Purpose: Ankylosing spondylitis (AS) patients with inadequate response to the first tumour necrosis factor-alpha antagonist (an..
Displaying the 2 most recent news articles by An Duy Tran.
Senior Research Fellow In Health Economics
Melbourne School Of Population And Global Health
Australian Health Economics Society (AHES)
The Professional Society for Health Economics and Outcomes Research (ISPOR)
Doctor of Philosophy
Wageningen University and Research Centre
Master of Science
Wageningen University and Research Centre